In late 2020, I looked at Zoom Video Communications, Inc. (ZM) and quickly determined shares were grossly overvalued. A few days ago, someone asked me for my opinion of the company. With the release of Q2 and YTD2024 results after the August 21 market close, I now revisit ZM. NOTE: ZM is NOT to be [...]
In my May 10 post, I disclose my decision to initiate a 200-share Agilent Technologies (A) position @ ~$127/share in a 'Core' account within the FFJ Portfolio. On June 9 and July 6, I acquired an additional 100 shares @ ~$115.96/share and ~$118.48/share. These purchases lowered my average cost to ~$122.35 and brought my total [...]
In my August 10 guest post at Dividend Power, I explain why I have no exposure to T. Rowe Price (TROW) and why I have no intention of initiating a position. In an industry where participants are heavily dependent on Assets Under Management (AUM) and performance track record relative to peers, TROW's struggles are [...]
I last reviewed Broadridge Financial Solutions (BR) in this November 29, 2022 post at which time it had recently released its Q1 2022 results. With the release of the Q4 and FY2023 results and FY2024 guidance, I take this opportunity to revisit this existing holding. Business Overview BR operates in two reportable segments, Investor Communication [...]
In my February 8, 2021 post, I disclose a new Merck & Co (MRK) position in a 'Core' account within the FFJ Portfolio with the purchase of 300 shares @ ~$75/share. I subsequently disclosed in this May 3, 2021 post the purchase of another 100 shares @ ~$75/share. Through the automatic reinvestment of the dividend [...]
I have been closely monitoring Paycom Software (PAYC) in that I have been a long-term Automatic Data Processing (ADP) and Paychex (PAYX) shareholder. I was tempted to initiate a PAYC position in early May. However, I opted to wait until the release of Q2 2023 results in early August and acquired Blackstone (BX), BlackRock (BLK), [...]
Following the release of Q1 2023 results, I analyzed West Pharmaceuticals (WST) to determine if I should increase my exposure. I conclude that WST's valuation is too rich in my May 1 post. On July 27, WST released its Q2 and YTD2023 and revised FY2023 guidance. I now revisit WST to determine if I should [...]
In my May 19 post, I disclose a new Thermo Fisher Scientific (TMO) position in the FFJ Portfolio. On May 24, I published a brief post in which I disclose an increase in my TMO exposure. I now hold 75 shares in a 'Core' account at an average cost of ~$509.61 and 52 shares in [...]
I last reviewed CME Group (CME) in this November 14, 2022 post at which time the most recently available financial information was for Q3 and YTD2022. At the time of that post, my CME exposure consisted of 382 CME shares in a 'Core' account and 321 shares in a 'Side' account within the FFJ Portfolio. [...]
This FFJ Portfolio - July 2023 report overviews my recent investment activity. Relative to July 2022, the value of the FFJ Portfolio has fallen by ~$ 27,609 CDN and increased by ~$785,022 USD. The increase is attributed to my concerted effort to increase my exposure to high-quality US companies. Purchases In The FFJ Portfolio In [...]